Min Jun(Crane Center)

网站: cranects.com/min-jun-do/

电话: +1 415-625-3230


Min Jun 隶属于旧金山的 Crane Center for Transgender Surgery.他在纽约大学医学院从 Dr. Rachel Bluebond-Langner 学习了机器人辅助阴道成形术的技术。他提供 SRS 及 SRS 修复的手术服务。Min Jun 现时(2022 年 2 月)的手术地点位于 San Francis Memorial Hospital.


Min Jun 所使用的技术为 Da Vinci 机器人辅助的腹膜阴道成形术。该技术从下腹开出 4-6 个 2cm 左右的刀口,并将机器人放进去,从腹部开始游离腹膜。他使用阴囊皮肤作为外部阴道皮肤以及阴唇皮肤;阴茎皮肤及龟头作为阴蒂附近的皮肤和阴蒂。这样的好处是因为阴蒂周围的皮肤得以保留,阴蒂的完整性和美观性可以得到增强。机器人接下来从内部缝合腹膜和皮肤的衔接部位,并完成手术。


  • Crane Center 要求至少有两封精神科医生的信和一封 HRT 医生的信(推荐信内容的具体要求在页面底部)
  • 必须在拿到推荐信之后才能开始预约手术
  • BMI 要求:强制要求低于 35,但是在正常范围内为最佳(因为伤口缝合原因)
  • 年龄要求:18 岁及以上无需家长同意,16 岁到 17 岁需要家长同意


  1. 在官网 Contact 处预约 Initial Consultation 并预留保险信息(必须写清保险信息才能约上)
  2. 签署 Initial Consultation 的知情同意书
  3. 参加 Initial Consultation,可以向 Min Jun 提问
  4. 拿到信之后发邮件预约手术
  5. 获得手术日期,可以选择加入 Cancellation list(如果前面有人取消有机会提前手术时间)
  6. 在临近手术日期时处理好保险问题,并在术前一个月内完成所需要的血液检查(会提前通过邮件发过来所有所需的东西)
  7. 手术两日前在 Crane Center 进行术前咨询
  8. 术后大约 2-3 天后出院,在 SF 附近休养
  9. 术后 7,14,21 天在 Crane Center 进行术后检查
  10. 术后 7 天后拆包,并开始通模具。一开始通模具的频率为一天 4 次,每次 15 分钟。之后会随时间减少次数。


现时(2022 年 2 月),Crane Center 旧金山接受的网络内保险有:

  • Cigna PPO
  • Blue Cross/Blue Shield PPO
  • Western Health Advantage
  • Shutter Select
  • San Francisco Health Plan/Healthy SF
  • EHN/WebTPA (Whole Foods)

其他 PPO 保险需要提前和 Crane Center 进行沟通。


  • Medicare
  • Medicaid
  • State Medi-Cal/Straight Medi-Cal/Fee-for-Service Medi-Cal
  • Tri-Care
  • Kaiser


(英文 Reddit 链接)


Two Letters from 2 different licensed mental health specialists

  • 1 letter can be from a provider who has only had an evaluative role
  • At least one of the letters must be from a provider with a doctorate level degree (Ph.D., Psy.D., etc.)
  • Texas patients: Blue Cross Blue Shield of Texas requires two letters from a Doctorate level provider (Ph.D., Psy.D. or Psychiatrist)
  • The mental health provider letter(s) must include ALL of the following:
    • Patient’s legal and preferred name
    • Patient’s date of birth
    • Date provider/patient relationship began and the frequency of contact
    • A statement that the patient has been diagnosed with persistent, well-documented gender dysphoria/gender identity disorder and exhibits all of the following:
    • The desire to live and be accepted as a member of the opposite sex, usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatment; and
    • The transgender identity has been present persistently for at least two years; and
    • The disorder is not a symptom of another mental health disorder; and
    • The disorder causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.
    • Documentation that the patient has completed a minimum of 12 continuous months of living in a gender role that is congruent with their gender identity, across a wide range of life experience and events that may occur throughout the year.
    • The patient has undergone a minimum of 12 continuous months of hormone therapy (recommended for bottom surgery and breast augmentation only).
    • A statement that the patient has the capacity to make fully informed decisions and to consent for treatment.
    • That the patient is able to comply with long term follow-up requirements and post- operative expectations have been addressed.
    • If the patient has significant medical or mental health issues present, they must be reasonably well controlled.
    • Any substance use (marijuana, alcohol, etc.) is well controlled for at least 6 months prior to the patient’s surgical date.
    • The provider must state their experience with treating patients diagnosed with gender dysphoria.
  • The letter from your Hormone Provider must include:
    • Patient’s legal and preferred name
    • Patient’s date of birth
    • Date provider/patient relationship began and the frequency of contact
    • Date hormone therapy began and the frequency of treatment
    • That the patient has undergone a minimum of 12 continuous months of hormone replacement therapy
    • If the patient has a contraindication to hormone therapy, please note this